252 related articles for article (PubMed ID: 27138763)
1. The Benefits and Side Effects of Bevacizumab for the Treatment of Recurrent Ovarian Cancer.
Zhang W; Shen Z; Luo H; Hu X; Zheng L; Zhu X
Curr Drug Targets; 2017; 18(10):1125-1131. PubMed ID: 27138763
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials.
Wu YS; Shui L; Shen D; Chen X
Oncotarget; 2017 Feb; 8(6):10703-10713. PubMed ID: 27793044
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer.
Haunschild CE; Tewari KS
Future Oncol; 2020 Mar; 16(7):225-246. PubMed ID: 31746224
[TBL] [Abstract][Full Text] [Related]
4. Critical appraisal of bevacizumab in the treatment of ovarian cancer.
Yoshida H; Yabuno A; Fujiwara K
Drug Des Devel Ther; 2015; 9():2351-8. PubMed ID: 25960638
[TBL] [Abstract][Full Text] [Related]
5. Impact of Bevacizumab on Clinical Outcomes in Patients With Platinum-resistant Relapsed Ovarian Cancer.
Seol A; Kim SI; Yoon HY; Lee M; Kim HS; Chung HH; Park NH; Song YS
In Vivo; 2024; 38(3):1338-1350. PubMed ID: 38688599
[TBL] [Abstract][Full Text] [Related]
6. Tolerability and Efficacy of Bevacizumab Monotherapy in Older Patients With Recurrent Ovarian Cancer.
Shintani D; Yoshida H; Yabuno A; Fujiwara K
In Vivo; 2020; 34(3):1451-1457. PubMed ID: 32354945
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab in ovarian cancer: A critical review of phase III studies.
Rossi L; Verrico M; Zaccarelli E; Papa A; Colonna M; Strudel M; Vici P; Bianco V; Tomao F
Oncotarget; 2017 Feb; 8(7):12389-12405. PubMed ID: 27852039
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial.
Bamias A; Gibbs E; Khoon Lee C; Davies L; Dimopoulos M; Zagouri F; Veillard AS; Kosse J; Santaballa A; Mirza MR; Tabaro G; Vergote I; Bloemendal H; Lykka M; Floquet A; Gebski V; Pujade-Lauraine E
Ann Oncol; 2017 Aug; 28(8):1842-1848. PubMed ID: 28481967
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and toxicity of bevacizumab in recurrent ovarian disease: an update meta-analysis on phase III trials.
Marchetti C; De Felice F; Palaia I; Musella A; Di Donato V; Gasparri ML; Musio D; Muzii L; Tombolini V; Panici PB
Oncotarget; 2016 Mar; 7(11):13221-7. PubMed ID: 26657509
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial.
Sorio R; Roemer-Becuwe C; Hilpert F; Gibbs E; García Y; Kaern J; Huizing M; Witteveen P; Zagouri F; Coeffic D; Lück HJ; González-Martín A; Kristensen G; Levaché CB; Lee CK; Gebski V; Pujade-Lauraine E;
Gynecol Oncol; 2017 Jan; 144(1):65-71. PubMed ID: 27871723
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab in recurrent ovarian cancer.
Sait Bakir M; Birge O; Karadag C; Ilhan Y; Aykut Tuncer H; Sezgin Göksu S; Simsek T
J BUON; 2021; 26(4):1271-1278. PubMed ID: 34564981
[TBL] [Abstract][Full Text] [Related]
12. Adding bevacizumab to single agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost effectiveness analysis of the AURELIA trial.
Wysham WZ; Schaffer EM; Coles T; Roque DR; Wheeler SB; Kim KH
Gynecol Oncol; 2017 May; 145(2):340-345. PubMed ID: 28291545
[TBL] [Abstract][Full Text] [Related]
13. Atezolizumab and Bevacizumab Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via Suppressing Epithelial-Mesenchymal Transition.
Zhang L; Chen Y; Li F; Bao L; Liu W
Front Immunol; 2019; 10():867. PubMed ID: 31105696
[TBL] [Abstract][Full Text] [Related]
14. Delta tocotrienol in recurrent ovarian cancer. A phase II trial.
Thomsen CB; Andersen RF; Steffensen KD; Adimi P; Jakobsen A
Pharmacol Res; 2019 Mar; 141():392-396. PubMed ID: 30639384
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
Pujade-Lauraine E; Hilpert F; Weber B; Reuss A; Poveda A; Kristensen G; Sorio R; Vergote I; Witteveen P; Bamias A; Pereira D; Wimberger P; Oaknin A; Mirza MR; Follana P; Bollag D; Ray-Coquard I
J Clin Oncol; 2014 May; 32(13):1302-8. PubMed ID: 24637997
[TBL] [Abstract][Full Text] [Related]
16. Antiangiogenic agents should be integrated into the standard treatment for patients with ovarian cancer.
Burger RA
Ann Oncol; 2011 Dec; 22 Suppl 8():viii65-viii68. PubMed ID: 22180405
[TBL] [Abstract][Full Text] [Related]
17. Long-term survival with bevacizumab in heavily pretreated and platinum-resistant mucinous ovarian cancer: A case report.
Tarumi Y; Mori T; Matsushima H; Kokabu T; Tsuchiya H; Kitawaki J
J Obstet Gynaecol Res; 2018 Feb; 44(2):347-351. PubMed ID: 29121427
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer.
Musa F; Pothuri B; Blank SV; Ling HT; Speyer JL; Curtin J; Boyd L; Li X; Goldberg JD; Muggia F; Tiersten A
Gynecol Oncol; 2017 Feb; 144(2):279-284. PubMed ID: 27931751
[TBL] [Abstract][Full Text] [Related]
19. Is FDA-Approved Bevacizumab Cost-Effective When Included in the Treatment of Platinum-Resistant Recurrent Ovarian Cancer?
Chappell NP; Miller CR; Fielden AD; Barnett JC
J Oncol Pract; 2016 Jul; 12(7):e775-83. PubMed ID: 27246689
[TBL] [Abstract][Full Text] [Related]
20. Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening.
Simpkins F; Belinson JL; Rose PG
Gynecol Oncol; 2007 Oct; 107(1):118-23. PubMed ID: 17658587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
